RT Journal Article
T1 Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.
A1 Rodriguez-Pinilla, Socorro Maria
A1 Domingo-Domenech, Eva
A1 Climent, Fina
A1 Sanchez, Joaquin
A1 Perez-Seoane, Carlos
A1 Lopez-Jimenez, Javier
A1 Garcia-Cosio, Monica
A1 Caballero, Dolores
A1 Blanco-Muñez, Oscar Javier
A1 Carpio, Cecilia
A1 Castellvi, Josep
A1 Martinez-Pozo, Antonio
A1 Gonzalez-Farre, Blanca
A1 Bendaña, Angeles
A1 Aliste, Carlos
A1 Gonzalez, Ana Julia
A1 Gonzalez-de-Villambrosia, Sonia
A1 Piris, Miguel A
A1 Gomez-Codina, Jose
A1 Mayordomo-Aranda, Empar
A1 Navarro, Belen
A1 Bellas, Carmen
A1 Rodriguez, Guillermo
A1 Borrero, Juan Jose
A1 Ruiz-Zorrilla, Ana
A1 Grande, Marta
A1 Montoto, Carmen
A1 Cordoba, Raul
K1 anaplastic large-cell lymphoma
K1 anaplastic lymphoma kinase
K1 complete response
K1 overall survival
K1 peripheral T-cell lymphoma
K1 progression-free survival
AB We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P 15% of cells were positive in anaplastic lymphoma kinase-positive and -negative anaplastic large-cell lymphoma and extranodal natural killer PTCL groups. We observed PTCL distribution across subtypes based on haematopathological re-evaluation. Poor prognosis, effect of specific prognostic indices, relevance of histopathological sub-classification, and response level to first-line treatment on outcomes were confirmed. Immune disorders amongst patients require further examination involving genetic studies and identification of associated immunosuppressive factors.
PB Wiley-Blackwell Publishing Ltd.
YR 2020
FD 2020-05-19
LK http://hdl.handle.net/10668/15594
UL http://hdl.handle.net/10668/15594
LA en
NO Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F, Sanchez J, Perez Seoane C, Lopez Jimenez J, et al. Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. Br J Haematol. 2021 Jan;192(1):82-99.
DS RISalud
RD Apr 20, 2025